{"groups":[{"description":"Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.","id":"FG000","title":"Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Three patients were accrued. Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm."}